Voyageur Pharmaceuticals Announces Board of Director Changes and 2nd quarter Financial Results
July 26, 2021 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”). Voyageur is very pleased to announce that Frank Wright and Ralph Hesje are being appointed to the Voyageur Board as Director’s effective immediately. Voyageur is committed to create a strong independent board of directors with extensive experience in board management, business development, business management, manufacturing & processing management, logistics, merger and acquisitions, strong backgrounds in corporate governance and ethics, and have track records of building multiple successful corporations.
Mr. Hesje is a senior executive having led a number of private and public companies as president, CEO and as a board member in Argentina, Brazil, USA and Canada. His first Board appointment was in 1993. He has served on non-profit, private and public company boards. His experience includes pipelines; oil and gas; civil construction; construction contracting; automation and waste management industries. With extensive experience in business start-ups, he currently is the Chair of a TEC Canada peer group coaching senior leaders on transformational change management, leadership excellence and enterprise success.
Mr. Wright is a senior executive with extensive P&L experience in both domestic and international industrial mineral operations with a successful record in creating joint ventures, initiating new operation start-ups, and leading acquisition activities. He is recognized as a strategic and innovative leader capable of achieving stretch goals in difficult and diverse business climates. His executive experience has been enhanced by broad-based functional line responsibility for marketing, product development, quality assurance, and operations management. He has served as a board member on several international joint venture companies and as the Chairman of the Board for the Chamber of Commerce in Highlands Ranch, Colorado.
Director Randy Henkle resigned as a director of Voyageur Pharmaceuticals. Voyageur would like to thank Mr. Randy Henkle for his many contributions to the company and we wish all the best in his current and future endeavours. Randy has been instrumental in the successful growth of our company and will be missed.
Voyageur also announces that it has filed second quarter Consolidated Financial Statements and Management Discussion and Analysis for the three and six months ended May 31, 2021. These documents can be viewed on Sedar at sedar.com.
Voyageur Pharmaceuticals Ltd. is a Canadian public company listed on the TSX Venture Exchange under the trading symbol VM. Voyageur is focused on the development of barite and iodine, Active Pharmaceutical Ingredient (API) minerals. The near-term focus is developing barium and iodine radio-contrast pharmaceutical products. Voyageur’s goal is to initially generate near term positive cash flow from operations using third party GMP pharmaceutical manufacturers in Canada and internationally. Ultimately, Voyageur has plans to build all the required infrastructure to become 100% self-sufficient with all manufacturing. Voyageur owns a 100% interest in three barium sulfate (barite) projects including two properties suitable in grade for the industrial barite marketplace, with interests in a potentially high-grade iodine, lithium & bromine brine project located in Utah, USA.
Voyageur is moving forward with its business plan of becoming the only fully-integrated company in the radiographic contrast medical field, by controlling all primary input costs under the motto of: “From the Earth to the Bottle”
For Further Media Information or to set up an interview, please contact:
President & CEO
Forward Looking Information
This news release may contain certain forward-looking information and statements, including, without limitation, statements pertaining to obtaining the necessary approvals of the TSX Venture Exchange. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR website at www.sedar.com. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.